Literature DB >> 61088

Tissue and hepatic subcellular distribution of liposomes containing bleomycin after intravenous administration to patients with neoplasms.

A W Segal, G Gregoriadis, J P Lavender, D Tarin, T J Peters.   

Abstract

1. Liposomes containing 111In-labelled bleomycin were injected intravenously into two patients. One patient had a hepatoma and the other had secondary adenocarcinomatous deposits in the liver. 2. The tissue distribution of 111In was determined by whole-body scanning and by measurement of the radioactivity in organs at autopsy. 3. Scans in vivo and post-mortem measurement of radioactivity indicated that liposomes accumulate predominantly in the liver, but that there is no selective uptake of liposomes by the malignant tissue. 4. The subcellular distribution of radioactivity in the liver was measured 90 min after injection by fractionation of percutaneous liver biopsies on sucrose density gradients. 5. Radioactivity within the liver was concentrated in lysosomes. 6. Electron microscopy of tissue obtained before the administration of liposomes revealed particles morphologically indistinguishable from liposomes in hepatoma cells and hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61088     DOI: 10.1042/cs0510421

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  8 in total

1.  Application of radioimmunoassay to monitor treatment of human cerebral gliomas with bleomycin entrapped within liposomes.

Authors:  G B Firth; M Firth; R O McKeran; J Rees; P Walter; D Uttley; V Marks
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

2.  Analytical subcellular fractionation of needle-biopsy specimens from human liver.

Authors:  T J Peters; C A Seymour
Journal:  Biochem J       Date:  1978-08-15       Impact factor: 3.857

3.  Multivesicular liposomes containing bleomycin for subcutaneous administration.

Authors:  R Roy; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 5.  Potential of liposomes as drug-carriers in cancer chemotherapy: a review.

Authors:  S B Kaye; V J Richardson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Kinetics and disposition of fluorescein-labelled liposomes in healthy human subjects.

Authors:  H G Eichler; J Senior; A Stadler; S Gasic; P Pfundner; G Gregoriadis
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients.

Authors:  V J Richardson; B E Ryman; R F Jewkes; K Jeyasingh; M N Tattersall; E S Newlands; S B Kaye
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

Review 8.  Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies.

Authors:  Francis Man; Twan Lammers; Rafael T M de Rosales
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.